2.3300 -0.02 (-0.85%)
After hours: 7:07PM EDT
|Bid||2.3500 x 1000|
|Ask||2.3900 x 1000|
|Day's Range||2.2600 - 2.4000|
|52 Week Range||1.5800 - 6.9800|
|Beta (3Y Monthly)||3.53|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.25|
Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. For example, we sympathize with anyone who was caught holding TransEnterix, Inc. (NYSEMKT:TRXC) duringRead More...
TransEnterix, Inc. , a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the fourth quarter and full year 2018.
TransEnterix, Inc. announced today that it plans to release fourth quarter and fiscal year 2018 financial and operating results before the market opens on Tuesday, February 26, 2019.
TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced the Company received FDA 510(k) clearance for its Senhance™ Ultrasonic System. “Advanced energy devices are used within a high percentage of cases across a wide range of procedures, which make them a critical tool for laparoscopic surgeons,” said Todd M. Pope, TransEnterix president and CEO.
A market downturn that hit biotech stocks across the board and a dilutive share offering pressured shares of the robotic surgery upstart.
On January 8, TransEnterix (TRXC) rose 11.15% compared to its previous closing price and reached $2.99 in its pre-market trading session. On January 7, TransEnterix issued a press release announcing its preliminary operational and financial performance for the fourth quarter and fiscal 2018. Based on the closing price on January 7, TransEnterix reported returns of 9.80% in the last week, -13.50% in the last month, and -53.70% in the last quarter.
TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today provided a corporate update, including preliminary unaudited revenue for the fourth quarter ended December 31, 2018. “2018 was a significant year for TransEnterix as we continued to drive the global commercial adoption of the Senhance System and made great strides towards expanding the applicability of the system to a greater number of surgeons and hospitals across the globe," said Todd M. Pope, president and CEO at TransEnterix.
From Iqvia to Red Hat to Xerium Technologies, executives and investors at top Triangle firms raked in millions by selling shares in 2018, U.S. Securities and Exchange Commission filings show.
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales have Read More...
Is Transenterix Inc (NYSEMKT:TRXC) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more resources than the average investor. The funds have access to […]
TransEnterix, Inc. announced today that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the 37th Annual J.P.
Investors need to pay close attention to TransEnterix (TRXC) stock based on the movements in the options market lately.
Intuitive Surgical’s (ISRG) stock price rose from $364.94 at the close of market on December 29, 2017, to $489.57 on November 23, 2018, reflecting a ~34% year-to-date rise.
TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced its naming to Deloitte’s 2018 Technology Fast 500TM, an annual ranking of the fastest growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors. “We’re thrilled to be recognized as one of Deloitte’s 2018 Technology Fast 500 companies,” said Todd M. Pope, TransEnterix president and CEO. “TransEnterix’s mission is to advance minimally invasive surgical capabilities through digital laparoscopy with the SenhanceTM Surgical System.
In November, of the five analysts covering TransEnterix (TRXC), three have given it “buy” or higher ratings, and two have given it “hold” ratings.
TransEnterix’s (TRXC) interest expense increased to $685,000 in the third quarter compared to $563,000 in the previous year’s period. TransEnterix’s net income rose from -$38.51 million in the third quarter of 2017 to -$20.21 million in the third quarter, translating to net EPS of -$0.10 in the third quarter. TransEnterix’s net EPS were -$0.26 in the third quarter of 2017.
For 2018 and 2019, TransEnterix’s gross margins are expected to be 41.40% and 48.76%, respectively, compared to its gross margin of 5.4% in 2017. In comparison, the 2018 gross margins of its peers Intuitive Surgical (ISRG), Johnson & Johnson (JNJ), and Stryker (SYK) are expected to be 71.01%, 70.43%, and 66.29%, respectively. TransEnterix incurred general and administrative expenses of $3.69 million in the third quarter compared to $2.92 million in the third quarter of 2017 primarily due to higher personnel costs and outsourced services expenses.
TransEnterix (TRXC) is a medical device company focused on digitizing the interface between surgeons and patients for the improvement of minimally invasive surgery. TransEnterix’s Senhance surgical system digitizes laparoscopic minimally invasive surgery and allows for robotic precision, haptic feedback, surgeon camera control, and improved ergonomics. TransEnterix generated total revenue of $5.42 million in the third quarter compared to $183,000 in the comparable period of 2017.